GLP-1 & Incretin Science

The Same Effect, Past the Point of Benefit

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Adverse effects divide into two kinds: those arising from something other than the intended action, and those that are the intended action carried too far. The second cannot be engineered away without weakening the drug, which makes it a different problem entirely.

Key facts

Type 1
Off-target or unrelated toxicity
Type 2
The intended mechanism, exceeded
Type 1 example
Idiosyncratic liver injury
Type 2 example
Gastroparesis from delayed emptying
Type 1 remedy
Improve selectivity
Type 2 remedy
Dose, titration, patient selection

Why the distinction is not academic

It determines whether the problem is soluble by chemistry. An off-target effect can in principle be engineered out by making a compound more selective, leaving the wanted action intact. An on-target effect taken too far cannot. Reducing it means reducing what the drug does, because they are the same thing.

How to tell which you are looking at

Ask whether the adverse effect would disappear in a hypothetically perfect version of the drug. Drug-induced liver injury would; it is not part of how any GLP-1 agonist is supposed to work. Gastroparesis would not, because delayed gastric emptying is the mechanism. That thought experiment separates the two reliably.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why on-target effects define a class

They appear across every compound sharing the mechanism, at every generation, regardless of design improvements. Gastrointestinal effects have persisted through liraglutide, semaglutide, tirzepatide and retatrutide and will persist in anything engaging the same receptor, because they follow from receptor pharmacology rather than from any particular molecule.

What can be done about them anyway

Dose, titration schedule and patient selection. If an effect scales with exposure, lower exposure reduces it. If it attenuates with time, gradual escalation limits the peak. If it affects some people much more, identifying them in advance helps. None of these removes the effect; they manage where on the curve someone sits.

The one route that could separate them

Finding that the wanted and unwanted effects run through different pathways after all. The 2024 Nature work on dissociable hindbrain circuits for satiety and aversion is exactly this. If appetite suppression and nausea are separable rather than one signal, then what looked like an inseparable on-target cost becomes a selectivity problem, which chemistry can address.

Why this framing helps in reading safety claims

A claim that a new compound has better tolerability means something different depending on the type. Improved selectivity against an off-target effect is a real advance. A lower rate of an on-target effect may simply reflect lower exposure or slower titration, which is a dosing statement rather than a molecular one.

Quick reference

Off-targetOn-target, exceeded
Arises fromSomething other than the mechanismThe mechanism itself
ExampleIdiosyncratic liver injuryGastroparesis
Engineered away?In principle, by selectivityNot without weakening the drug
Managed byBetter moleculesDose, titration, selection

Frequently asked questions

How do I tell the two apart?

Ask whether the effect would disappear in a hypothetically perfect version of the drug. If it is the mechanism, it would not.

Why do gastrointestinal effects persist across every generation?

They follow from receptor pharmacology rather than from any particular molecule, so improved design does not remove them.

Can an on-target effect ever be separated?

Only if the wanted and unwanted effects turn out to run through different pathways, which the 2024 work on dissociable hindbrain circuits suggests may be possible.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.